The Valley Desk

NCT02927769 · Interventional trial

A Study of Nivolumab Plus Brentuximab Vedotin in Patients Between 5 and 30 Years Old, With Hodgkin's Lymphoma (cHL), Relapsed or Refractory From First Line Treatment

Overall registry status Completed

Phase 2

Conditions Hodgkin Disease

Delaware Valley sites

First posted

Registry updated

Added to the directory

View this study on ClinicalTrials.gov